| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.35B | 20.14B | 20.00B | 18.29B | 16.84B |
| Gross Profit | 12.64B | 7.08B | 7.03B | 6.52B | 6.03B |
| EBITDA | 6.78B | 5.67B | 5.62B | 5.41B | 4.99B |
| Net Income | 1.11B | 993.00M | 841.00M | 1.61B | 1.66B |
Balance Sheet | |||||
| Total Assets | 59.61B | 58.02B | 56.14B | 54.05B | 47.99B |
| Cash, Cash Equivalents and Short-Term Investments | 2.62B | 869.00M | 864.00M | 974.00M | 723.00M |
| Total Debt | 31.46B | 29.78B | 27.45B | 25.14B | 20.97B |
| Total Liabilities | 43.03B | 41.23B | 38.83B | 36.41B | 31.92B |
| Stockholders Equity | 15.78B | 15.62B | 16.11B | 16.57B | 15.12B |
Cash Flow | |||||
| Free Cash Flow | 2.35B | 1.46B | 1.29B | 1.16B | -928.00M |
| Operating Cash Flow | 4.87B | 4.85B | 4.50B | 4.81B | 4.39B |
| Investing Cash Flow | -3.04B | -3.70B | -4.75B | -5.41B | -5.47B |
| Financing Cash Flow | -74.00M | -1.14B | 139.00M | 848.00M | 953.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | C$28.38B | 4.04 | 43.97% | 3.94% | 2.75% | 342.54% | |
73 Outperform | C$13.30B | 13.87 | 35.31% | 2.69% | -0.29% | 15.30% | |
71 Outperform | C$13.30B | 13.87 | 35.31% | 2.70% | -0.29% | 15.30% | |
69 Neutral | C$28.38B | 4.15 | 43.97% | 3.89% | 2.75% | 342.54% | |
63 Neutral | C$33.04B | 4.71 | 31.99% | 7.42% | 0.11% | 7109.23% | |
60 Neutral | $48.67B | 4.58 | -11.27% | 4.14% | 2.83% | -41.78% | |
54 Neutral | C$28.16B | 24.88 | 7.68% | 9.49% | 2.42% | 24.37% |
TELUS plans to partially redeem C$500 million of its 2.75% Notes, Series CZ due July 8, 2026, on May 8, 2026, out of a total C$800 million outstanding. The notes will be selected on a pro rata basis, with the redemption price set under the existing indenture, and will be funded using proceeds from the company’s Fixed-to-Fixed Rate Junior Subordinated Notes issued in December 2025.
The transaction reflects TELUS’ ongoing balance sheet management as it refinances near-term debt with longer-dated, subordinated securities, potentially strengthening its capital structure ahead of the notes’ maturity. The move may also lower refinancing risk and provide additional financial flexibility as the company continues to invest in its core communications, health and digital businesses.
The most recent analyst rating on (TSE:T) stock is a Hold with a C$19.00 price target. To see the full list of analyst forecasts on Telus stock, see the TSE:T Stock Forecast page.
TELUS will amend its Dividend Reinvestment and Share Purchase Plan effective April 1, 2026, reducing the discount on shares issued from treasury for dividend reinvestment to 1.75 per cent off the average market price, while optional cash purchases will be made at full market value. The change, applying to shareholders of record as of March 11, 2026, fine-tunes the economics of its DRISP for Canadian and U.S. investors and may modestly adjust the company’s equity funding mix and attractiveness of share-based dividend reinvestment without altering overall access to the program.
Eligible shareholders in Canada and the United States can continue to reinvest dividends or enroll in the DRISP through Computershare, while non-registered holders are directed to work through their intermediaries. By maintaining the program with a lower discount rather than eliminating it, TELUS balances ongoing investor participation incentives with a more measured approach to share issuance from treasury, which could help manage dilution while preserving an efficient capital-raising tool.
The most recent analyst rating on (TSE:T) stock is a Hold with a C$19.00 price target. To see the full list of analyst forecasts on Telus stock, see the TSE:T Stock Forecast page.
TELUS has appointed TD Securities and Jefferies as financial advisors to guide the monetisation and partnership strategy for its TELUS Health business, which it describes as a rapidly growing, globally scaled digital health asset with a growing AI-focused product set. The company aims to bring in a strategic partner to enhance TELUS Health’s capabilities, customer reach and financial resources, and views the initiative as a key lever in its broader deleveraging plan, targeting a gradual reduction in net debt to adjusted EBITDA over the next several years and supporting long-term value creation through disciplined capital allocation and a strong free cash flow outlook.
The most recent analyst rating on (TSE:T) stock is a Buy with a C$21.00 price target. To see the full list of analyst forecasts on Telus stock, see the TSE:T Stock Forecast page.
TELUS announced that its leadership, including President and CEO Darren Entwistle and several board members, acquired 357,090 TELUS shares in the open market over November and December, bringing collective insider holdings to about 2.4 million shares. Entwistle has also been taking his entire salary in TELUS shares since 2024 and intends to continue, underscoring management’s alignment with shareholders and confidence in the company’s long-term value.
The company also disclosed it has repurchased and cancelled nearly 2.3 million common shares at an average price of $17.39 as part of a $500 million normal course issuer bid launched in December 2025, a move it says reflects the disconnect between its share price and underlying business fundamentals. TELUS framed the buybacks as complementary to its deleveraging program and phased reduction of its dividend reinvestment plan, citing strong operations and free cash flow growth that support an accelerated path to lower leverage targets through 2027, which could bolster investor confidence and strengthen its financial position in the telecom sector.
The most recent analyst rating on (TSE:T) stock is a Buy with a C$21.00 price target. To see the full list of analyst forecasts on Telus stock, see the TSE:T Stock Forecast page.
TELUS Corporation has announced the full redemption of its C$600 million 3.75% Notes, Series CV, which were due on March 10, 2026. This strategic financial move is set to take place on January 16, 2026, and reflects TELUS’s proactive management of its financial obligations, potentially impacting its financial positioning positively. The redemption aligns with TELUS’s commitment to leveraging its financial strategies to support its operations and maintain its industry standing.
The most recent analyst rating on (TSE:T) stock is a Buy with a C$25.00 price target. To see the full list of analyst forecasts on Telus stock, see the TSE:T Stock Forecast page.